Article

Sanofi, Regeneron Win U.S. Approval for Cancer Medicine

Regeneron Pharmaceuticals Inc. (REGN) (REGN)

Sanofi (SAN) and won U.S. clearance for Zaltrap as a treatment for patients with advanced colorectal cancer who haven’t been helped by previous therapy.

The Food and Drug Administration approved the drug for use in combination with chemotherapy as a so-called second-line treatment for patients whose colorectal cancer has spread to other parts of the body, the agency said today in a statement. Regeneron also sells the medicine, known by the scientific name aflibercept, under the name Eylea to treat wet age-related macular degeneration, a condition that causes vision loss.

Read the full story: http://tinyurl.com/cu3d22j

Source: Bloomberg Businessweek

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo